Risk Factors and Characteristics of COVID 19 Infection in Patients With Haematological Diseases
NCT ID: NCT04930731
Last Updated: 2021-06-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
60 participants
OBSERVATIONAL
2021-09-30
2022-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
2. assessment of characteristics of covid 19 in haematological patients
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Using Mixed-methods Approach to Explore the Long-term Effects of COVID-19
NCT05303103
Quantification of Binding and Neutralizing Antibody Levels in COVID-19 Vaccinated Health Care Workers Over 1 Year
NCT04910971
Safety and Immunogenicity of COVID-19 Vaccine Booster in Patients With Liver Diseases
NCT05204602
Intrafamilial Transmission of Hepatitis B Virus: Frequency, Risk Factors, and Role of Hepatitis B Vaccination
NCT05523921
Assessment of Long-term Impact Post COVID-19 for Patients and Health Care Professionals of the European Hospital
NCT04525911
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In the following weeks, infections spread across China and other countries around the world .
The Chinese public health, clinical, and scientific communities took action to allow for timely recognition of the new virus and shared the viral gene sequence to the world .
On January 30, 2020, the World Health Organization (WHO) declared the outbreak a Public Health Emergency of International Concern
. On February 12, 2020, the WHO named the disease caused by the novel coronavirus "coronavirus disease 2019" (COVID-19) .
A group of international experts, with a range of specializations, have worked with Chinese counterparts to try to contain the outbreak .
Preliminary reports suggest that patients with an underlying malignancy have inferior outcomes.
While haematology patients are thought to be at increased risk of developing severe complications both due to immune dysfunction from their underlying haematological disorder and immunosuppressive therapies used for treatment, delays in treatment of the underling malignancy may compromise patient safety and survival. Data from other cohorts worldwide suggest mortality from COVID-19 is higher in haematology patients compared to the general population, with reported mortality rates between 39% and 50% in other British haematology patient cohorts.
In particular, a recent UK case series reported significantly higher case fatality rates in haematology patients receiving immunosuppressive or cytotoxic therapy within three months of COVID-19 diagnosis, raising concerns about the delivery of systemic anti-cancer therapy (SACT) during the pandemic.
There is an ongoing need to share collective experience regarding the clinical course of COVID-19 in patients with haematological disorders, particularly regarding implications for SACT delivery, in order to enable patients to receive treatment in a timely and safe manner during the pandemic.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients with age more than 18 years old
Exclusion Criteria
* Patients who refuse to contribute in this study.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ayah Ibrahim Nemr
Resident doctor at haematology unit ,, internal medicine department ,, assiut university
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Blimark C, Holmberg E, Mellqvist UH, Landgren O, Bjorkholm M, Hultcrantz M, Kjellander C, Turesson I, Kristinsson SY. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015 Jan;100(1):107-13. doi: 10.3324/haematol.2014.107714. Epub 2014 Oct 24.
Hilal T, Gea-Banacloche JC, Leis JF. Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections. Blood Rev. 2018 Sep;32(5):387-399. doi: 10.1016/j.blre.2018.03.004. Epub 2018 Mar 16.
Chemaly RF, Ghosh S, Bodey GP, Rohatgi N, Safdar A, Keating MJ, Champlin RE, Aguilera EA, Tarrand JJ, Raad II. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore). 2006 Sep;85(5):278-287. doi: 10.1097/01.md.0000232560.22098.4e.
Pinana JL, Gomez MD, Montoro J, Lorenzo I, Perez A, Gimenez E, Gonzalez-Barbera EM, Carretero C, Guerreiro M, Salavert M, Sanz G, Hernandez-Boluda JC, Borras R, Sanz J, Solano C, Navarro D. Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients. Transpl Infect Dis. 2019 Oct;21(5):e13158. doi: 10.1111/tid.13158. Epub 2019 Sep 3.
Whimbey E, Englund JA, Couch RB. Community respiratory virus infections in immunocompromised patients with cancer. Am J Med. 1997 Mar 17;102(3A):10-8; discussion 25-6. doi: 10.1016/s0002-9343(97)80004-6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COVID 19 &haematological pts
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.